Abstract
In cancer treatment, the pervasive late effects of radiation and chemotherapy limit their utility, especially in children, in whom treatment often leads to lifelong morbidity and excess mortality. Advances in understanding the molecular pathways related to tumorigenesis have led to the development of targeted therapies, but recurrent late effects, as in the case of trastuzumab, and unexpectedly high rates of cardiotoxicity highlight gaps in our understanding of drug pathways and the mechanisms of treatment toxicity. Here, we review the mechanisms of anthracycline activity in tumor and cardiac cells, as well as the clinical manifestations and their associated cardiotoxicity, prevention strategies, and monitoring recommendations. We also describe the cardiac effects of trastuzumab with specific attention to its interaction with anthracyclines.
| Original language | English (US) |
|---|---|
| Title of host publication | Cardiovascular Toxicology |
| Publisher | Elsevier Inc. |
| Pages | 432-446 |
| Number of pages | 15 |
| Volume | 13-15 |
| ISBN (Electronic) | 9780081006122 |
| ISBN (Print) | 9780081006016 |
| DOIs | |
| State | Published - Dec 15 2017 |
| Externally published | Yes |
Fingerprint
Keywords
- Adverse effects
- Antineoplastic antibiotics
- Cancer survivorship
- Cardiac biomarkers
- Cardiomyopathy
- Cardioprotection
- Cardiotoxicity
- Congestive heart failure
- Dexrazoxane
- Doxorubicin
- Echocardiography
- Epirubicin
- Idarubicin
- Late effects
- Mitoxantrone
- Monitoring
- Neuregulin
- Trastuzumab
ASJC Scopus subject areas
- Medicine(all)
Cite this
Anthracycline, Trastuzumab, and Cardiovascular Toxicity. / Cochran, T. R.; Franco, V. I.; Scully, R.; Lipshultz, Steven E.
Cardiovascular Toxicology. Vol. 13-15 Elsevier Inc., 2017. p. 432-446.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Anthracycline, Trastuzumab, and Cardiovascular Toxicity
AU - Cochran, T. R.
AU - Franco, V. I.
AU - Scully, R.
AU - Lipshultz, Steven E
PY - 2017/12/15
Y1 - 2017/12/15
N2 - In cancer treatment, the pervasive late effects of radiation and chemotherapy limit their utility, especially in children, in whom treatment often leads to lifelong morbidity and excess mortality. Advances in understanding the molecular pathways related to tumorigenesis have led to the development of targeted therapies, but recurrent late effects, as in the case of trastuzumab, and unexpectedly high rates of cardiotoxicity highlight gaps in our understanding of drug pathways and the mechanisms of treatment toxicity. Here, we review the mechanisms of anthracycline activity in tumor and cardiac cells, as well as the clinical manifestations and their associated cardiotoxicity, prevention strategies, and monitoring recommendations. We also describe the cardiac effects of trastuzumab with specific attention to its interaction with anthracyclines.
AB - In cancer treatment, the pervasive late effects of radiation and chemotherapy limit their utility, especially in children, in whom treatment often leads to lifelong morbidity and excess mortality. Advances in understanding the molecular pathways related to tumorigenesis have led to the development of targeted therapies, but recurrent late effects, as in the case of trastuzumab, and unexpectedly high rates of cardiotoxicity highlight gaps in our understanding of drug pathways and the mechanisms of treatment toxicity. Here, we review the mechanisms of anthracycline activity in tumor and cardiac cells, as well as the clinical manifestations and their associated cardiotoxicity, prevention strategies, and monitoring recommendations. We also describe the cardiac effects of trastuzumab with specific attention to its interaction with anthracyclines.
KW - Adverse effects
KW - Antineoplastic antibiotics
KW - Cancer survivorship
KW - Cardiac biomarkers
KW - Cardiomyopathy
KW - Cardioprotection
KW - Cardiotoxicity
KW - Congestive heart failure
KW - Dexrazoxane
KW - Doxorubicin
KW - Echocardiography
KW - Epirubicin
KW - Idarubicin
KW - Late effects
KW - Mitoxantrone
KW - Monitoring
KW - Neuregulin
KW - Trastuzumab
UR - http://www.scopus.com/inward/record.url?scp=85043339024&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043339024&partnerID=8YFLogxK
U2 - 10.1016/B978-0-12-801238-3.95641-1
DO - 10.1016/B978-0-12-801238-3.95641-1
M3 - Chapter
AN - SCOPUS:85043339024
SN - 9780081006016
VL - 13-15
SP - 432
EP - 446
BT - Cardiovascular Toxicology
PB - Elsevier Inc.
ER -